How a TB mutation rewires bacteria to survive pyrazinamide

Tuberculosis treatment relies on key drugs such as pyrazinamide (PZA) to shorten therapy, but resistance to PZA complicates care. Many cases of PZA resistance are linked to mutations in the pncA gene, yet it has been unclear how those mutations reshape the bacterium’s overall activity. In work led by Kannan Palaniyandi, researchers compared a clinical Mycobacterium tuberculosis strain carrying a 10-nucleotide deletion in pncA (positions 118-127) with a standard laboratory strain H37Rv to see how each responds at the gene-expression level when exposed to PZA and when left untreated. That 10-nucleotide deletion abolishes PZA activation and was identified in the team’s earlier study. The authors established critical drug concentrations for the experiments: 200 µg/mL for the clinical strain (CST) and 12.5 µg/mL for the H37Rv strain (RvT), using an untreated H37Rv strain (UTRv) as the reference. By directly comparing treated and untreated cultures, the study aimed to reveal the broader transcriptional adaptations linked to mutation-driven resistance rather than focusing only on the pncA change itself.

The team used RNA-sequence profiles from treated and untreated cultures and applied differential expression analysis, functional enrichment, KEGG pathway mapping, and protein-protein interaction network analysis to interpret results. They found 3,413 differentially expressed genes (padj ≤ 0.05), including 1,428 upregulated and 1,360 downregulated genes. Functional enrichment was strongest in CST vs. RvT and CST vs. UTRv, while RvT vs. UTRv showed no significant enrichment, highlighting the dominant effect of the pncA mutation on the PZA response. Ribosomal machinery genes rplC, rplD, and rpsH were significantly enriched and strongly upregulated in the mutant strain under treatment but only mildly regulated in the laboratory strain. Several anti-TB drug targets, including katG, ethA, atpE, and panD, were downregulated, while efflux pumps Rv1258, Rv3008, and Rv3756c were upregulated, suggesting cross-resistance mechanisms. Network analysis identified 19 clusters, with prominent modules formed by polyketide synthases, PDIM synthesis genes, fatty acid β-oxidation enzymes and the ESX secretion system, pointing to coordinated metabolic and structural responses.

Taken together, these findings show that PZA resistance in this clinical isolate is not a passive, dormant state but an active, metabolic adaptation driven by the pncA mutation and PZA exposure. The mutant strain upregulated genes linked to cell damage repair, lipid biosynthesis for the cell envelope, and ATP maintenance for energy production, while repressing genes that promote dormancy and virulence. The coordinated upregulation of ribosomal components and the activation of modules involved in lipid metabolism and secretion suggest the bacterium retools both its metabolism and cell surface to persist under drug pressure. Changes in other anti-TB drug targets and efflux pumps raise the possibility of cross-resistance, meaning resistance to PZA could affect sensitivity to other drugs. By connecting specific mutation-driven transcriptomic changes to adaptive pathways, the work provides a clearer map of how resistant strains survive and points toward potential targets for diagnostics or new interventions to overcome tolerance.